Vivione Biosciences Inc. (“Vivione”) (TSX:VBI), through its wholly owned
subsidiary, Vivione Biosciences, LLC, is pleased to announce that it
will begin a clinical pilot evaluation of its RAPID-B platform at the
prestigious Cleveland Clinic Department of Pathology.
Vivione will apply its highly sensitive and quantitative RAPID-B
platform technology to urinary tract infection screenings through the
pilot. Early internal data from Vivione has shown that RAPID-B can be
used for the initial screening of urine specimens prior to any culture
requirements to determine true infection versus contamination. The
RAPID-B platform has the ability to deliver test results at the time of
specimen delivery, which is up to 48 hours faster than a traditional
urine culture. With its ability to quickly deliver quantitative results,
this technology can reduce laboratory resource needs and associated
expenditures.
"We’re excited about the opportunity to work with Dr. Gary Procop on the
clinical pilot study,” said Vivione's Chief Medical Officer, Matthew
Gombrich, M.D., M.S. “Dr. Procop has a long history of evaluating novel
clinical technologies for improved efficiency and cost savings. We
believe this is a great step for Vivione as we grow our clinical
presence and are confident that the data coming out of this evaluation
will allow Vivione to initiate the formal clinical development process.”
About Vivione
Vivione is a TSX Venture Exchange listed biosciences company focused on
the commercialization of its proprietary RAPID-B system; an integrated
system of hardware, software and chemical reagents that quickly and
accurately identify, quantify and qualify bacteria and other pathogens
in food safety, bio-therapeutics, clinical, industrial and oil & gas
environments. For more information, visit www.VivioneBiosciences.com.
Cautionary Statements
This news release contains "forward-looking statements" within the
meaning of applicable securities laws. Although Vivione believes that
the expectations reflected in its forward-looking statements are
reasonable, such statements have been based on factors and assumptions
concerning future events that may prove to be inaccurate. These factors
and assumptions are based upon currently available information to
Vivione. Such statements are subject to known and unknown risks,
uncertainties and other factors that could influence actual results or
events and cause actual results or events to differ materially from
those stated, anticipated or implied in the forward-looking statements.
This news release contains forward-looking information relating to the
commercialization and the development of the RAPID-B system, Vivione’s
business and growth strategy and the commercialization and the
development of the Molecular Design technology. Readers are cautioned to
not place undue reliance on forward-looking statements. The statements
in this news release are made as of the date of this news release and,
except as required by applicable law, Vivione does not undertake any
obligation to publicly update or to revise any of the included
forward-looking statements, whether as a result of new information,
future events or otherwise. Vivione undertakes no obligation to comment
on analyses, expectations or statements made by third-parties in respect
of Vivione, or its financial or operating results or (as applicable),
their securities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER
(AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE)
ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Copyright Business Wire 2014